CriticalOxazolidinone antibiotic×Antidepressant (other antidepressants, N06AX)
Updated · Methodology
Mechanism
Vortioxetine acts on serotonin receptors and inhibits the serotonin transporter, which returns serotonin to the neuron (vortioxetine summary of product characteristics, SmPC, European Medicines Agency, EMA, section 5.1). Linezolid is an antibiotic that reversibly and non-selectively inhibits monoamine oxidase (MAO), although it has no antidepressant effect at antibacterial doses (linezolid SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 4.4). According to the European vortioxetine SmPC, drugs that affect serotonin metabolism, MAO inhibitors included, raise the risk of serotonin syndrome and neuroleptic malignant syndrome, and both can be life-threatening (vortioxetine SmPC, EMA, section 4.4). Serotonin syndrome, including fatal cases, has been reported when linezolid was combined with serotonergic drugs (linezolid label, US Food and Drug Administration, FDA, section 5.3). The two drugs do not interact through cytochrome P450 (CYP) enzymes. CYP2D6 is the main enzyme that metabolises vortioxetine, with a smaller role for CYP3A4/5 and CYP2C9 (vortioxetine SmPC, EMA, section 5.2). Linezolid does not inhibit these enzymes, and they do not metabolise it to any detectable extent (linezolid SmPC, AEMPS, section 4.5).
Symptoms
The main risk of the combination is serotonin syndrome (vortioxetine summary of product characteristics, SmPC, European Medicines Agency, EMA, sections 4.4 and 4.5; vortioxetine label, US Food and Drug Administration, FDA, section 5.2). It presents with changes in consciousness (agitation, hallucinations, coma), autonomic instability (fast heart rate, labile blood pressure, hyperthermia), neuromuscular signs (hyperreflexia, incoordination), nausea, vomiting or diarrhoea (vortioxetine SmPC, EMA, section 4.4). The US vortioxetine label adds delirium, dizziness, sweating, flushing, tremor, rigidity, myoclonus and seizures (FDA vortioxetine label, section 5.2). When linezolid is combined with serotonergic drugs, the Spanish linezolid SmPC lists cognitive dysfunction, very high fever, hyperreflexia and incoordination as the signs to watch for (linezolid SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 4.4). The US linezolid label reports fatal cases with such combinations (FDA linezolid label, section 5.3).
Management
The combination is contraindicated. The European vortioxetine summary of product characteristics (SmPC) contraindicates non-selective monoamine oxidase (MAO) inhibitors and names linezolid as a weak reversible non-selective MAO inhibitor (vortioxetine SmPC, European Medicines Agency, EMA, sections 4.3 and 4.5). The US label prohibits starting vortioxetine in a patient being treated with linezolid (vortioxetine label, US Food and Drug Administration, FDA, sections 4 and 5.2). If a patient taking vortioxetine needs linezolid, stop vortioxetine before starting linezolid (FDA vortioxetine label, section 5.2). If the combination cannot be avoided, give the added drug at the minimum dose under close monitoring for serotonin syndrome (vortioxetine SmPC, EMA, section 4.5). The linezolid SmPC does not allow linezolid with serotonergic drugs either, unless the combination is absolutely necessary, in which case the patient needs close monitoring (linezolid SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 4.4). With serotonin reuptake inhibitors, the SmPC does not allow linezolid unless close blood pressure monitoring is possible (linezolid SmPC, AEMPS, section 4.3). No document gives an interval between a linezolid course and vortioxetine. The European vortioxetine SmPC gives 14 days only for irreversible non-selective MAO inhibitors (vortioxetine SmPC, EMA, section 4.5), and the US label gives 14 and 21 days only for MAO inhibitors used for psychiatric disorders (FDA vortioxetine label, sections 2.4 and 4). In serotonin syndrome, stop vortioxetine at once and start symptomatic treatment (vortioxetine SmPC, EMA, section 4.4), stop other serotonergic drugs immediately as well (FDA vortioxetine label, section 5.2). The linezolid SmPC advises considering stopping one or both drugs (linezolid SmPC, AEMPS, section 4.4).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Zyvox (linezolid) prescribing information (2026)– FDA, DailyMed setid 6e70e63b-bfd5-478d-a8ee-8ba22c9efabd (Pharmacia & Upjohn), version 72, revised 06/2026, sections 4.2, 5.3, 5.9, 7.1, 7.2 and 12.3
- AEMPS: Ficha técnica: Linezolid, Zyvoxid 600 mg (nº registro 64109) (2026)– AEMPS, CIMA, nº registro 64109 (Zyvoxid 600 mg comprimidos recubiertos con película), revisión 05/2026, secciones 4.3, 4.4 y 4.5
- EMA: Ficha técnica: Vortioxetina – Brintellix (EU/1/13/891), sección 4.4 (2026)– EMA, SmPC Brintellix (EU/1/13/891), texto en CIMA nº 113891010, información del producto actualizada 19/01/2026, secciones 4.3, 4.4, 4.5 y 5.1
- EMA: Ficha técnica: Vortioxetina – Brintellix (EU/1/13/891), sección 4.3 (2026)– EMA, SmPC Brintellix (EU/1/13/891), texto en CIMA nº 113891010, consultado 20.10.2026, sin fecha de revisión en CIMA, secciones 4.3, 4.5 y 5.2
- FDA: TRINTELLIX (vortioxetine) tablets prescribing information (Takeda) (2025)– FDA, DailyMed setid 1a5b68e2-14d0-419d-9ec6-1ca97145e838 (Takeda Pharmaceuticals America), revisión 02/2025 (versión 18, vigente desde 05.03.2025), secciones 2.4, 4, 5.2 y 7.1